From Wikipedia, the free encyclopedia
Content deleted Content added
|
 |
|||
| Line 1: | Line 1: | ||
|
Multiple endocrine neoplasia type 4 is a rare sub-type of [[Multiple endocrine neoplasia]].<ref name=”auto”>{{Citation |last=Ahmed |first=Fahad W. |title=Multiple Endocrine Neoplasias Type 4 |date=2025 |work=StatPearls |url=http://www.ncbi.nlm.nih.gov/books/NBK568728/ |access-date=2026-02-02 |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=33760487 |last2=Majeed |first2=Muhammad S. |last3=Kirresh |first3=Omar}}</ref> The condition is commonly referred to as “MEN4”. |
Multiple endocrine neoplasia type 4 is a rare sub-type of [[Multiple endocrine neoplasia]].<ref name=”auto”>{{Citation |last=Ahmed |first=Fahad W. |title=Multiple Endocrine Neoplasias Type 4 |date=2025 |work=StatPearls |url=http://www.ncbi.nlm.nih.gov/books/NBK568728/ |access-date=2026-02-02 |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=33760487 |last2=Majeed |first2=Muhammad S. |last3=Kirresh |first3=Omar}}</ref> The condition is commonly referred to as “MEN4”. |
||
|
According to the National Library of Medicine, “in MEN4, there is a mutation in the [[Cyclin-dependent kinase inhibitor protein|cyclin-dependent kinase inhibitor]] 1B gene (”CDKN1B”).”<ref name=”auto”/> |
According to the National Library of Medicine, “in MEN4, there is a mutation in the [[Cyclin-dependent kinase inhibitor protein|cyclin-dependent kinase inhibitor]] 1B gene (”CDKN1B”).”<ref name=”auto”/> |
||
| Line 9: | Line 9: | ||
|
== References == |
== References == |
||
|
{{Reflist}} |
{{Reflist}} |
||
|
[[Category:Endocrine neoplasia]] |
|||
Latest revision as of 16:41, 7 February 2026
Multiple endocrine neoplasia type 4 is a rare sub-type of Multiple endocrine neoplasia.[1] The condition is commonly referred to as “MEN4”.
According to the National Library of Medicine, “in MEN4, there is a mutation in the cyclin-dependent kinase inhibitor 1B gene (CDKN1B).”[1]
The clinical manifestations of MEN type 4 include hyperparathyroidism, pituitary adenomas, and tumors. [2]
While it was formerly called “MENX”, the condition was renamed “MEN4” at the 11th International Workshop on MENs in Delphi, Greece. [3]
- ^ a b Ahmed, Fahad W.; Majeed, Muhammad S.; Kirresh, Omar (2025), “Multiple Endocrine Neoplasias Type 4”, StatPearls, Treasure Island (FL): StatPearls Publishing, PMIDÂ 33760487, retrieved 2026-02-02
- ^ Frederiksen, Anja; Rossing, Maria; Hermann, Pernille; Ejersted, Charlotte; Thakker, Rajesh V.; Frost, Morten (2019-09-01). “Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases”. The Journal of Clinical Endocrinology and Metabolism. 104 (9): 3637–3646. doi:10.1210/jc.2019-00082. ISSN 1945-7197. PMC 6637788. PMID 30990521.
- ^ Alevizaki, M.; Stratakis, C. A. (July 2009). “Multiple endocrine neoplasias: advances and challenges for the future”. Journal of Internal Medicine. 266 (1): 1–4. doi:10.1111/j.1365-2796.2009.02108.x. ISSN 1365-2796. PMC 3138202. PMID 19522821.
